Fcγ receptor predictive genomic testing and the treatment of indolent non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 5, 2010, Pages 321-322

  Treon, Steven ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FC RECEPTOR; FC RECEPTOR IIIA; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G2; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; EDITORIAL; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENOME; GENOMICS; GENOTYPE; HUMAN; MONOTHERAPY; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; GENETIC POLYMORPHISM; GENETICS; NOTE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, GENETIC; RECEPTORS, IGG;

EID: 79952278207     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.063     Document Type: Editorial

References (15)

1. Zhuang Y, Xu W, Shen Y, et al. FcγR polymorphisms and clinical efficacy of rituximab in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010, in press.
2. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8. (Pubitemid 34525533)
3. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7. (Pubitemid 46606207)
4. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:474-81. (Pubitemid 46224224)
5. Paiva M, Marques PM, Martins A, et al. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 2008; 183:35-40. (Pubitemid 351637610)
6. Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3A genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group Trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract 111.
7. Hunter ZR, Yang G, Ioakimidis LI, et al. Association of CR/VGPR with progression-free survival in rituximab-naive WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in FcγRIIIA-158. J Clin Oncol 2010; 28(15 suppl):600s (abstract 8108).
8. Pierz K, Gu S, Lewis M, et al. Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy in follicular non-Hodgkin's lymphoma. J Clin Oncol 2010; 28(15 suppl): 589s (abstract 8065).
9. Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010; 28(15 suppl):574s (abstract 8004).
10. Warmerdam PA, van de Winkel JG, Vlug A, et al. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147:1338-43.
11. Hatjiharissi E, Hansen M, Santos DD, et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7:286-90. (Pubitemid 46408193)
12. Lejeune J, Thibeault G, Ternant D, et al. Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in white patients, and for an FcγRIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26:5489-91.
13. de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156:3948-55.
14. Mössner E, Brnker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402.
15. Yang G, Gong P, Xu L, et al. Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F. J Clin Oncol 2010; 28(15 suppl):601s (abstract 8112)